ATE469212T1 - Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase- aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon - Google Patents
Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase- aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davonInfo
- Publication number
- ATE469212T1 ATE469212T1 AT06849419T AT06849419T ATE469212T1 AT E469212 T1 ATE469212 T1 AT E469212T1 AT 06849419 T AT06849419 T AT 06849419T AT 06849419 T AT06849419 T AT 06849419T AT E469212 T1 ATE469212 T1 AT E469212T1
- Authority
- AT
- Austria
- Prior art keywords
- sequence
- dyskerin
- gse
- telomerase activity
- nucleotides
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title abstract 3
- 102100031249 H/ACA ribonucleoprotein complex subunit DKC1 Human genes 0.000 title abstract 2
- 101710167047 H/ACA ribonucleoprotein complex subunit DKC1 Proteins 0.000 title abstract 2
- 108010017842 Telomerase Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000032683 aging Effects 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 206010062759 Congenital dyskeratosis Diseases 0.000 abstract 1
- 230000001133 acceleration Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502511A ES2325431B1 (es) | 2005-10-14 | 2005-10-14 | Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones. |
| PCT/ES2006/070152 WO2007090911A1 (es) | 2005-10-14 | 2006-10-11 | Secuencia de nucleótidos y péptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtención, composiciones terapéuticas y sus aplicaciones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469212T1 true ATE469212T1 (de) | 2010-06-15 |
Family
ID=38344881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06849419T ATE469212T1 (de) | 2005-10-14 | 2006-10-11 | Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase- aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9074194B2 (OSRAM) |
| EP (1) | EP1947175B1 (OSRAM) |
| JP (1) | JP5560398B2 (OSRAM) |
| AT (1) | ATE469212T1 (OSRAM) |
| CA (1) | CA2625981A1 (OSRAM) |
| DE (1) | DE602006014574D1 (OSRAM) |
| DK (1) | DK1947175T3 (OSRAM) |
| ES (2) | ES2325431B1 (OSRAM) |
| PT (1) | PT1947175E (OSRAM) |
| WO (1) | WO2007090911A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2334736B1 (es) * | 2007-11-23 | 2011-02-02 | Consejo Superior De Investigaciones Cientificas (Titular Al 90%) | Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular. |
| WO2014122346A1 (es) * | 2013-02-05 | 2014-08-14 | Consejo Superior De Investigaciones Cientificas (Csic) | Bionanopartículas biodegradables para liberación del péptido gse24-2, procedimiento de obtención y utilización |
| PT3061815T (pt) * | 2013-10-25 | 2020-05-18 | Univ Madrid Autonoma | Péptidos derivados de gse 24.2 para o tratamento de doenças causadas pelo stresse oxidativo e danos no adn |
| CN114364392B (zh) * | 2019-05-02 | 2025-12-16 | 德克萨斯大学系统董事会 | 涉及tert激活治疗剂的方法和组合物 |
| EP4681700A1 (en) | 2023-03-17 | 2026-01-21 | Consejo Superior De Investigaciones Científicas - CSIC | Gse24.2-derived peptide and uses thereof |
| ES2989543A1 (es) * | 2023-05-22 | 2024-11-26 | Alodia Farm S L U | Peptidos para su uso en la prevencion y/o tratamiento de radiodermitis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| DE19817118C1 (de) * | 1998-04-17 | 1999-10-28 | Deutsches Krebsforsch | Dyskerin und dafür codierende DNA-Moleküle, diese enthaltende Vektoren, Antikörper gegen Dyskerin und die Verwendung dieser Gegenstände |
-
2005
- 2005-10-14 ES ES200502511A patent/ES2325431B1/es not_active Expired - Fee Related
-
2006
- 2006-10-11 CA CA002625981A patent/CA2625981A1/en not_active Abandoned
- 2006-10-11 AT AT06849419T patent/ATE469212T1/de active
- 2006-10-11 DK DK06849419.4T patent/DK1947175T3/da active
- 2006-10-11 PT PT06849419T patent/PT1947175E/pt unknown
- 2006-10-11 JP JP2008535049A patent/JP5560398B2/ja not_active Expired - Fee Related
- 2006-10-11 DE DE602006014574T patent/DE602006014574D1/de active Active
- 2006-10-11 WO PCT/ES2006/070152 patent/WO2007090911A1/es not_active Ceased
- 2006-10-11 US US12/090,215 patent/US9074194B2/en not_active Expired - Fee Related
- 2006-10-11 EP EP06849419A patent/EP1947175B1/en active Active
- 2006-10-11 ES ES06849419T patent/ES2360238T3/es active Active
-
2015
- 2015-06-16 US US14/740,890 patent/US9587002B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2625981A1 (en) | 2007-08-16 |
| ES2325431A1 (es) | 2009-09-03 |
| EP1947175A1 (en) | 2008-07-23 |
| US9587002B2 (en) | 2017-03-07 |
| ES2325431B1 (es) | 2010-06-28 |
| JP5560398B2 (ja) | 2014-07-23 |
| DK1947175T3 (da) | 2010-09-27 |
| WO2007090911A1 (es) | 2007-08-16 |
| ES2360238T3 (es) | 2011-06-02 |
| US20090202503A1 (en) | 2009-08-13 |
| US20150337022A1 (en) | 2015-11-26 |
| DE602006014574D1 (de) | 2010-07-08 |
| US9074194B2 (en) | 2015-07-07 |
| JP2009511036A (ja) | 2009-03-19 |
| EP1947175B1 (en) | 2010-05-26 |
| PT1947175E (pt) | 2010-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
| IL213319A (en) | Polylysis peptides for use in the treatment of bacterial infections | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| EP1548032A4 (en) | KDR-PEPTIDES AND VACCINES CONTAINING THEM | |
| ZA200800533B (en) | Glycosylated IL-7, preparation and uses | |
| DE602004001727D1 (de) | Verfahren zur herstellung cyclischer peptide | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| WO2005023866A3 (en) | Peptides that inhibit complement activation | |
| WO2009103105A3 (en) | Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders | |
| WO2007076162A3 (en) | Antimicrobial cathelicidin peptides | |
| ATE506957T1 (de) | Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen | |
| DE602005020165D1 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| HRP20171694T1 (hr) | Novi pripravci i postupci | |
| NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
| IL206157A (en) | Pancreatic elastase protein of type 1, a nucleic acid molecule encoded by a protein | |
| WO2008040190A8 (fr) | Petits peptides pour anti-angiogenèse et utilisation de ceux-ci | |
| NZ596043A (en) | Allergy inhibitor compositions and kits and methods of using the same | |
| UA122856C2 (uk) | Варіантний інсектицидний ген ахмі115 та способи його застосування | |
| WO2010103515A3 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| DE602006014574D1 (de) | Sequenz von nukleotiden und peptiden gse 24.2 aus dyskerin zur herbeiführung von telomerase-aktivität, herstellungsverfahren dafür sowie therapeutische zusammensetzungen und anwendungen davon | |
| WO2006095347A3 (en) | VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS | |
| WO2017140913A3 (en) | Fusion proteins | |
| ATE549399T1 (de) | Verfahren zur herstellung von pravastatin | |
| WO2006067469A3 (en) | Compositions comprising opa protein epitopes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1947175 Country of ref document: EP |